Cellebrite DI (NASDAQ:CLBT) CEO Sells $2,150,183.07 in Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CEO Thomas Hogan sold 139,713 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total value of $2,150,183.07. Following the completion of the sale, the chief executive officer directly owned 790,548 shares in the company, valued at approximately $12,166,533.72. The trade was a 15.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Cellebrite DI Stock Performance

Shares of NASDAQ CLBT traded down $4.45 during trading on Thursday, reaching $10.80. The stock had a trading volume of 36,666,491 shares, compared to its average volume of 2,106,110. The business’s 50-day moving average price is $14.59 and its 200-day moving average price is $14.09. Cellebrite DI Ltd. has a fifty-two week low of $9.58 and a fifty-two week high of $19.98. The company has a market cap of $2.69 billion, a P/E ratio of 38.57, a PEG ratio of 1.99 and a beta of 1.18.

Institutional Trading of Cellebrite DI

A number of large investors have recently made changes to their positions in CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its stake in Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares during the last quarter. Advisory Services Network LLC acquired a new position in Cellebrite DI during the 3rd quarter worth approximately $40,000. CWM LLC increased its position in shares of Cellebrite DI by 57.0% in the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after purchasing an additional 889 shares during the last quarter. First Horizon Corp grew its stake in shares of Cellebrite DI by 421.8% during the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after purchasing an additional 2,337 shares in the last quarter. Finally, Elevation Wealth Partners LLC purchased a new position in Cellebrite DI in the second quarter valued at $44,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Cellebrite DI

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Cellebrite reported second-quarter adjusted earnings of $0.11 per share, above the $0.06 consensus estimate, and highlighted rising subscription revenue in its first-half results. The company also raised its adjusted EBITDA target. Cellebrite Appoints Shiven Ramji Chief Executive Officer and Reports Second-Quarter 2026 Results
• Positive Sentiment: Unusually heavy call-option activity—19,988 contracts purchased versus an average of 586—suggested that some traders were positioning for a rebound or higher future prices, although options activity does not guarantee a change in fundamentals.
• Neutral Sentiment: Cellebrite appointed Shiven Ramji as chief executive officer, succeeding Thomas E. Hogan. The transition could bring a new growth strategy, but it also adds uncertainty while the company is lowering its outlook. Cellebrite CEO Appointment and Second-Quarter Results
• Neutral Sentiment: Two executives reported small stock sales totaling 641 shares. The transactions reduced their individual holdings by less than 0.2% and appear unlikely to materially affect the investment case.
• Negative Sentiment: Second-quarter revenue was $131.14 million, slightly below the $131.87 million analyst estimate. One earnings analysis also characterized adjusted earnings of $0.11 per share as below its $0.12 estimate, reinforcing concerns about execution. Cellebrite Q2 Earnings and Revenues Miss Estimates
• Negative Sentiment: Management lowered full-year 2026 revenue guidance to $555 million-$561 million from a consensus estimate of $568.1 million and forecast third-quarter revenue of $145 million-$148 million versus $150.3 million expected. The company also lowered its full-year ARR outlook.
• Negative Sentiment: Ademi LLP and Block & Leviton separately announced investigations into potential securities-law violations and allegedly inaccurate company statements. These announcements increase legal and reputational risk, although they represent claims under investigation rather than established wrongdoing. Ademi LLP Cellebrite Investigation

Wall Street Analyst Weigh In

CLBT has been the topic of several research reports. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Needham & Company LLC reduced their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Finally, DA Davidson increased their target price on shares of Cellebrite DI from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, Cellebrite DI currently has an average rating of “Moderate Buy” and a consensus target price of $21.80.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.